, Singapore
218 views
Photo by Tima Miroshnichenko on Pexels

Cordlife assures continuity of operations amidst possible licence suspension

Unaudited 1H2025 results support the company’s outlook.

Cordlife Group Limited said it will be able to continue as a going concern for at least the next 12 months, even if its Ministry of Health (MOH) licence is suspended.

The company’s board said a detailed assessment, including cash flow forecasts up to 30 September 2026, shows Cordlife can maintain operations based on its current financial position and liquidity.

Cordlife added that its unaudited first-half 2025 results support this view.

However, the Board cautioned that there are still “significant uncertainties” and no assurance that the company will not face challenges ahead.

MOH had earlier notified Cordlife of its intention to suspend the company’s cord blood banking and human tissue banking licence for one year, following investigations into temperature issues affecting several cryogenic storage tanks.

If the suspension proceeds, Cordlife will continue to face fixed and operating costs despite a halt in business. The company may also face refunds, possible customer claims, and regulatory penalties.

Cordlife said it will keep monitoring its financial position and update shareholders on any material developments.

 

Join Singapore Business Review community
Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.